Compare Nasdaq Inc (NDAQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nasdaq Inc trades at $90.25 (market cap $51.96B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Nasdaq Inc is far larger — about 34× Recursion Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NDAQ | RXRX | |
|---|---|---|
Market Cap | $51.96B | $1.53B |
Sector | Financials | Health |
52-Week High | $100.98 | $6.79 |
52-Week Low | $76.85 | $2.84 |
Enterprise Value | $59.02B | $946.50M |
Dividend Yield | 1.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
